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A human choline kinase eDNA was cloned by complementation f the yeast choline kina~ mutation, cki, from a human glioblastoma eDNA 
expression library. The deduced sequence of the human enzyme comprised 456 amino acids with a calculated relative molecular mass of 52.065. 
The human enzyme resembled the rat liver enzyme over the entire se,4uen¢~. It also resembled the yeast enzyme in the carbox~-terminal region, 
but not much in the amino-terminal region. 
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1. INTRODUCTION 
It is generally accepted that cholinephosphate cyti- 
dylyltransferase plays a major role in the regulation of 
phosphatidylcholine synthesis (for a review, see [1]). But 
recently a regulatory role of choline kinase in phosphat- 
idylcholine synthesis has also been suggested (for a re- 
view, see [2]). To elucidate the regulatory mechanism of 
choline kinase, its eDNA and gene would be extremely 
useful. DNA encoding choline kinase has been isolated 
from two sources, yeast and rat liver, in our laboratory 
[3,4]. The yeast gene was obtained by complementation 
of the choline kinase mutation, cki [5,6], and rat liver 
choline kinase DNA was recently cloned, using specific 
antibodies, from a 2gtl I rat liver eDNA library. The 
open reading frames in the yeast and rat liver clones 
encoded 582 and 435 amino acid residues with relative 
molecular masses of 66,316 and 49,737, respectively. 
Recently, several mammalian eDNAs were success- 
fully cloned by complementation of the corresponding 
yeast mutations [7-12], but so far no successful cloning 
of eDNAs for phospholipid metabolism has been re- 
ported. Here we demonstrate he cloning of a mammal- 
ian eDNA encoding choline kinase by complementation 
of the yeast cki mutation from a human glioblastoma 
eDNA library constructed by Colicelli et al. [11]. The 
results raises the possibility that other mammalian 
¢DNAs involved in phospholipid metabolism would 
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also be available through yeast eomplementation (for 
yeast phospholipid metabolism mutants, see review 
[13]). 
2. MATERIALS AND METHODS 
2. I. Yeast strains attd eDNA library 
Wild.type strain X2180.1A (a S UC2 ntal mel gal2 CUP1) was pro- 
vided by the Yeast Genetic Stock Center (University of California). 
Phosphatidylserine synthase mutant 657 (a pss) was isolated as an 
¢thanolamine auxotroph from ~X2180-1A as described previously [14]. 
cki disruptant 2013 (=cki::HIS3 leu2 his3 trial canl) was constructed 
Essentially as described previously [3], except hat the genE was dis- 
rupled by inserting HIS3 [15] between the Bglll and BamHl sites of 
the coding frame. Cloning strain D493-2 (apss ckl::HIS3 teu2 his3 trpl 
canl) was constructed from 667 and 2013 by the standard genetic 
method. The composition of the inositol-free minimum medium (M-i 
medium) was as described previously [16]. The human glioblastoma 
eDNA library [11] was a gift from M, Wiglet (Cold Spring Harbor 
Laboratory) to J.N. 
2.2. Materials 
Restriction ¢ndonacleases and other reagents were obtained from 
Takara Shuzo (Kyoto) and Nippon Gene (Toyama). [0t-3-'P}dCTP (4129 
Ci/mmol) and [tnerhyl-=~Clcholine chloride (52.0 Ci/mol) were pur- 
chased from Amersham Corp. and DuPont-New England Nuclear. 
respectively, 
3. RESULTS AND DISCUSSION 
3.1. Ciotffng strategy 
Mutants defective only in the choline kinase gene 
(CKI) do not show any apparent growth phenotype [6], 
and are thus not suitable for ¢omplementation cloning. 
We introduced cki into the pss background to construct 
a cki pss double mutant. The pss mutation defective in 
phosphatidylserine synthase causes auxotrophic re- 
quirement for serine, ethanolamine, or choline [14]. 
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When 20/.tg/ml inositol was added to the culture, the 
requirement for ethanolamine and choline was more 
pronounced, and serine was no longer effective, proba. 
bly due to a further decrease in phosphatidylserine syn- 
thesis caused by inhibition of the synthase by inositol 
[17] and by the lowered availability of CDPdiaeylglyc- 
erol. When the cki mutation ':.'as added to this psa back- 
ground, the resulting double mutant was unable to grow 
on choline because the c:.-t' mutation prevented choline 
utilization. Transformation of the double mutant with 
choline kinase eDNA should restore growth. Thus we 
thought hat a choline kinase eDNA could be obtained 
by complementation of the cM mutation in the ck~ pss 
mutant. 
3.2. Cloning of a human eDNA capable of complement. 
/rig the yeast eki mutation 
We cultured D493-2 (a pss ekL"HIS3 leu2 h~s3 trpl 
can1) in inositol-free minimum medium (M-i) supple- 
mented with 20,ug/ml leucine, 20 ~g/'ml tryptophan and 
200:tg/ml serine to the logarithmic phase at 23°C. Com- 
petent ceils were prepared and transformed with a 
human glioblastoma eDNA library [I 1] by the method 
of Ito et al. [18]. The library had been constructed on 
yeast expression vector pADANS [11] containing the 
ADH1 promoter and 14 amino acids derived from 
ADHI, and the Notl cloning site. Thus the cDNAs 
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Fi~. 1, Incorporation of [methyl.~C]choline i to phosphatidylcholine 
in mutant D49~-2 (0)and its transformant carr~in~ pHGCKI-I (O). 
I:)493-2 and D49~-2 [pHGCKI-I] were l]rown in M-i medium supple- 
mented with 20/~g/ml leu¢ine, 20/ag/ml tryptophan and 200 ,ug/ml 
serine to the logarithmic phase (Asso, 0.3-0,5), To 1 ml of each culture 
was added 0.1 ,uCi [methyl-~C]choline (10 Ci/mol), and then th~ mix- 
ture were incubated at 30°C for the indicated times with shaking. 
Lipids wer~ extract~ as described previously [19] and separated on 
a Silica Gel 60 plate (Merck) with chloroform/methanol/acetic acid/
88% formic acid/water (35:15:6:2:0,25, v/v) as the solvent system. The 
gel containing phosphatidylcholine was scraped off and counted in a 
toluene/Triton X-100 scintillant, 
could be expressed under the control of the ADH1 pro- 
moter in yeast cells. In this experiment, we used 10 lag 
of the library per 109 ceils, and cultured the transfor- 
taunts for one week on one minimum plate supple- 
mented with 20 ,ug/ml each of inositol, choline and tryp- 
tophan. From five such plates, we obtained 9 colonies. 
Seven were found to contain identical plasmids carrying 
a 2.4-kbp insert. We named this plasmid, pHOCKI-I. 
The other two colonies contained plasmids with smaller 
inserts, 1.8 and 1.6 kbp, and were not studied further. 
Upon retransformation with purified pHGCKI-I, 
D493-2 acquired the ability to grow on choline in the 
presence of 20 ~g/ml inositol. The transformant did not 
grow without choline, indicating that the plasmid com- 
plemented the c/ci mutation, but not the pss mutation. 
3.3. pHGCKI-I encodes choline kinase 
To confirm that pHGCKI-1 encodes choline kinase, 
we first examined whether or not the plasmid could 
restore the activity of the CDPcholine pathway in the 
parental strain by determining the incorporation of 
[methyl-~C]choline into phosphatidylcholine. Fig. 1 
shows that parental strain D493-2 incorporated the la- 
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Fig. 2. Choline kina~e activity of the D493-2 transformant harboring 
pl-tQCKl°l, D493-2 harboring pHGCKI-I was cultured in 250 ml of 
M-i medium supplemented with 20/.tg/ml tryptophan and 200/.~g,/ml 
serine, and harvested at th-* mid-logarithmic phase, The soluble frac- 
tion of the cells was prepared, and 6.8/.tg was incubated for 10 rain 
at 30°C in a 10/~1 assay mixture containing the same ingredients as 
deserib~ previously [3] except hat the concentration of [methyl- 
~C]eholine (52 Ci/mol) ~vas reduced to 0.37 n'tM. A 9/.tl portion of the 
reaction mixture was directly spotted onto a Silica Gel 60 plate 
(Merck), and then the plate was developed with 95% ethanol/2~b 
ammonium hydroxide (1:1, v/v). Autoradio~raphy was carried out for 
2 days at room temperature with Fuji X-ray film. (Lane 1) Complete 
system; (lane 2) minus ATP: (lane 3) 10 mM EDTA instead of 1MgSO~; 
(lane 4) the reaction mixture was boiled for i rnin at the end of the 
incubation and then treated with 10 units of calf intestine alkaline 
phosphatase for 10 rain at 37"C; (lane 5) boiled enzyme. SF, solvent 
front; O, origin; CDP-Cho, CDPcholine; P-eho, phosphoryleholine; 
Cho, cho|ine. 
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belled choline at a very low rate, but the transformant 
carrying pHGCKI-1 at a much faster rate. The rate was 
comparable to that in the case of wild type X2180-1A 
(data not shown). Thus pHGCKI-I restored the CDP- 
choline pathway in the mutant. Next, we assayed the 
choline kinase activity. A 100,000xg supernatant was 
prepared, and incubated with [methylJ~C]cholinc and 
ATP in the presence of Mg ~" for l0 rain at 30°C. After 
incubation, the reaction mixture was directly applied 
onto a Silica Gel H plate. The plate was developed and 
then autoradiographed. As shown in Fig. 2, the 
100,000xg supernatant of the pHGCKI-I transformant 
produced phosphorylcholine (lane l). The phosphory]- 
choline formation was dependent on ATP (lane 2) and 
Mg ~* (lane 3). Alkaline phosphatase treatment con- 
vetted the reaction product to choline (lane 4), confirm- 
ing the identity of the product. Heat treatment abol- 
ished the activity (lane 5). The present results show that 
pHGCKI-1 carries choline kinas¢ eDNA. When choline 
kinas¢ activity was assayed by the method described 
previously [20], the activities of the transformant and 
untransformed cells were 6 and 0.1 nmol.min-l.mg -~ 
protein, respectively. Thus the choline kinase activity of 
the transformant was comparable to or even higher 
than that in rat tissues [20-22]. We concluded that the 
cloned eDNA contained a considerable length, or even 
the full-length of the choline kinase coding frame. 
3.4. Nucleotide 8equenee of a hush,an choline kinase 
eDNA 
The 2.4-kbp insert was excised from pHGCKI-I with 
Nod, and then the 2,408-bp sequence was determined 
by the didcoxy chain termination method [23] after sub- 
cloning into M 13 mpl0 and mpl I [24]. As shown in Fig. 
3, there was a large open reading frame capable of 
encoding 465 amino acid residues. As expired, the 
reading frame was in-frame with the ADHI leader pep- 
tide in expression vector pADANS [11]. Since it was not 
known whether translation started at the first methion- 
ine or a further upstream one. we compared the deduced 
amino acid sequence with the recently determined rat 
liver choline kinasc sequence [4]. 
3.5. Sequence comparison with choline k#~ase from other 
sources 
In Fig. 4, the deduced amino acid sequence, starting 
from methionin¢-I as the first amino acid, is aligned 
with that of rat liver choline kinase. The first 23 amino 
acids of both sequences perfectly matched each other, 
strongly suggesting that methionin¢-I is the transla- 
tional start site of human glioblastoma choline kina~. 
Furthermore, with some deletions or insertions, the rat 
liver and human glioblastoma enzymes howed a high 
degree of sequence similarity over their entire lengths; 
84.9% amino acids were identical and 9% conservative. 
C~CGCOT00TCGGC~CCTGTOGGGCATG~CCA~TTCTOC~CCGGGOOOGAGGCG 60 
M K [ ~ F 0 T 0 G g A 11 
GAGCCCTCG~00TC~GCTOCTGCTGAGCTGCG~TA00GGOAGCGOGG~CGGCGCCC 120 
[ P 5 P L G L L L 5 C 0 S G S A A P A P 31 
GGGGTG~GGGAGOAGGGCGAOGOOGGOAGGG~OGTC~A~TOCAAOCA~TO~COAACA 160 
G V G Q O ~ D A A 5 D L [ $ g O L A P T 51 
~CCG~CTCGCGCTOCCC~TCCGCCGCCGCTG~GCTGCCGGTGCC00TGCC~AGCGO 240 
A ~ L A L P P P P P L P L P L P L P Q P T1 
CGG00GCCGCAG~CGCC~GCAOACGAGCA~CCO~OCCCCOOGOGCOGCOCA~CCTAT 300 
P P P Q P P A D E 0 P E P R A R R R A Y 91 
CTGTGGTGCAAGGAOTTCCTGCCCGGCGCCTGGCOGG000TCCGCOAGOACGAOTTCCAO 360 
L N C K E F L P G h N ~ G L R E D E F 1t 111 
ATG~GTGlCATOAOAOGCOGOOTTAGCA~CATOCTGTTCCAOTGCTCCCTA~TGACACC 420 
l 5 V I R 0 G L 5 N H L F Q C S LP  D ~ 131 
AOAGCCA00CTTG~TG~TGAGCCTCGG~A~GTGCTCCTGCG00TGTATGOAGOG~TTTTG 480 
T A T L G D E P R g V L L ~ L Y G A I L 151 
CAGATOAG~TCOTOTA^TAAAOAO~OAT00GAACA~GCTCAGA~G~AATG~TTTC~ 540 
~ H fl S C N K E G S K Q A Q K K H E F Q 171 
GGGGGTGAGGCCATOGTTCTGGAGAGCOTTATGTTT~O~T10TCOCAOAOA~GTCACTT 600 
G A E A H Y L E S V H F A ] L ~ E R $ L 191 
O~C~AACTCTATG~CATCTTTCCCC~GGCCGACTG~A00~T~CATGCCGAGCC~ 660 
G P K L Y 0 I F P Q G R L E Q F I P S K 211 
CGATT~G~T~CTGAAO~ATTAAGTTI'OCCAGATATTTCTO~ATCOCCGA~TG 720 
R L D T E E L 8 L P D l 5 A E I A E K ~ 231 
GCTAC~TTTCATGOTATG~TGCCMTC~TA~DOAAA~TGGGTTTTTGOGAOA 700 
A T ~ H 0 H K H P F N K E P K ~ L F G T 251 
~T~GA~GTATGTAA~OG~GT~CTOAO~TT~ATTTACTGAGG^MCO~O~ATTA~ ~40 
H EK  Y L g E V L R I K F T E E 5 6 1K  271 
AA~TCCACA~TTGCTCAGTTAOA~TCT00CCTTOOAA~ZGO~COTGAO~TO~TTGK L It K L L S Y N L P L g L g N L fl S L ~ 
OTT~TOTAOTCCATOTOCAOTTGTATTTTG~CATAATGACTOTC~G~GGTAATATC 9rio 
L K S T P S P V V F C li N D C 0 E 0 H 1 311 
TTGTT~TGOAA~CG~AG~TTCTG~OAGA~CTgMGOTC^TTOMTT~ 1020 
L L L E G~ [ H $ E K O K L H L ] D F E 331 
TACAGG~TTAC~TTACAGGGOATTCOACATTGOA~TCACTT~T~T0~GT~ATGTAT 10flo 
Y S S Y N Y R G F 0 [ ~ N I I  F G E ~ H Y ~51 
OAT TATA~,OT ATGAb.AAATACOCT  TT'['[CAGAGCAAACATCCGC, A,AGT ATCCCACCAAG 1140 
O Y S Y £ K Y P F F R A N ] R K 'f P T K 371 
bJLACi'~ACAGCTCCATTTTATTTnCkGTTACTT00gTGC^ TTCCAAAAl"OACTTTOAAAAC 1200 
~ 0 O L II F 1 8 5 Y L P .A F O N D F £ tl 391 
OTCAQT ^ CT G.~r:-~AAATCC~T T.~I"A,'~,~GAAGAAMGT TOOT TGAAGTTAM^GGT 1T 1260 
L 5 T E E K S I l K E E M L L E ¥ N R F 411 
GCCC [TGCATCT(~K'f T TC~TO'IGGOOACTGTGGTCCkTTGTACAA00CAAGATTICMCT 1]20 
A L A $ II F L il G L M S 1V  O A K I S 5 431 
AT T G/LAT T T GGGT ACMGGACTACGCCCAAGC/LAGGTT GK'i'~TAT T TCCAe.,CAGAAG 1~.60 
I E F 0 Y H D ¥ A O A R F D A Y F It Q K 451 
A~GP, AO.C T TP-- ~C~ TGTGACTG fLIGGGA(i'~ AC'[CCA~OCACCTCATCAC'[GGACT00AT~ 1440 
B K L G V '~ 456 
GGAGGCAGCAG~GCGC~T 00 CCTC T GTGCT 1(,~GAGT AGTC.(,~1CCTGTGOqA ~/LC-.OCTT 1500 
"I'C'd'.,GTG00TCACTACTG~CACATGTGTA'IGATACTAk,AGACG.GTM TAAAM'GGAGGGA 1560 
COT T TAT T T CATCTC'r TOT T T,~C~.AT T CACTA(]GACTCAGAAACGAGATCGGGA,~,~ 1620 
A/~AT/U[^ GT~,~MAGTC, C~ATCTGTGAMOC TI"T TA/~TC TAI?.,AC,.~AO,~P.,MI TCATA 1680 
TT T GGGGGC TAAGGT  T CGAGT,C, AGMGA~A,ei.ACAC-CAAGAGT/~,AG.OAGTGT Le,,CT O 1140 
CAGOTACTI T~TTAAT GTT(IACT T TA,~.~T T TTCATGAAT GTGC TGGTGAACACI"GTGAC 1800 
CAGGGT T T T OT,~,G,~T~CGACTGTGTTATAGAC()GTC-CI"C ACTCCCAADQGAC~GT 1860 
0 A00 A G AG M GT AC TGCI~,AGT C00~AG TC A~'I Cd."G T00~GGT C,~".4~0 TCT(~CC TGC, GOC 1920 
OGTCC,~,G/L~,OCTGCTCCT T ~C00TCTTGGTCCCATCT00T G~GCGGA00AGCTGGA'[TG 1960 
C T C T C, GA C-¢AP.~,.C AAOC-.-.-.-.-.-.-.-~C C 00~ ACT 0 TCd] AO ACAC, AC-C TC'[ CCC CT CCT GC'I 00GCG TG T 2040 
G TG[~C/'~CTGTAGAGTT TCAG'[GT/I, CTCGATGTOACT CTCCCCI"C-CCC'1TCCT00'I'GATG 210Q 
G AGTGTC-CAGACA000ATGCGTG00CAOGG¢,G'~,CAGTGTG I^',OP,00TCgCTGTOT~ 2160 
TCCCCTCCCAOGGAGCA~CT00Tl"QACCTAGCTC1TTGGGCCTCTCCTGCCCTCTC-CTCT 2220 
C-CCTGGAGIGTC~ATCC TGTGAGI'AG4.~TGGGCCTCC~CTGGC, CAOGGT ICT00~GGC 2260 
CGGT T TCCCGGC00 T TACCAkACC TG,~,T 000(,~¢TGAC^TC/ffCMTC't "i'GTG~AGACAO 2)40 
CAOCCTGTAI"OTGGIGI"GGGOCGTGG,~',T CGAGTGTAOCTG'[GAAAI"OCATMMA 1"~ 2400 
TGTCCAAT 2408 
Fig, 3, Nucleotid¢ sequence and deduced amino acid sequence of haman glioblastoma choline kinasc cDNA. The sewlucnce was ~x~scd from 
pHGCKI-I  using Notl and determined by the did¢o~y chain termination method [23]. The Nod site is not shown in the figure. The numbers at 
the right denote the positions of the last nuclcotide and amino acid of each line. Amino acids are numbered with the first methionine taken as position 
I. The stop codon is indicated by an asterisk, Brcnncr's phosphotransfcras¢ consensus [25] is indicated by underlinings. 
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HKTRFCTGGEAEPSPLGLLLSCGSGSAAPAPGVGQORDAASDLESKOL-APTAALALPPP 
i l i l l i l l l i l l i i l l l l l l l l l  I i i l l  : I l i i l i i l l l  : :  l i i | l l  | ' l * l  . . . .  I i td l i  
HKTKFCTGGEAEPSPLGLLLSCG-GSAAPTPGYGQQRDAACELESKOLGGRSQPLALPP~ 
PPLPLPLPLPOPPPPC~ADEGPEPRARRRAYLWCKEFLPGAWRGLRKDEFIflSVIRC, GL 
i i  • i1111  i l l~ l  1 t l I I i I 4~I i l I ID i i I I I I I I I I I i l I I I { I I I I t l I I i i  
PP-P.PLPLP.PPPSPPLADEQPKP~T~R~AYLICKEFLPGAiRGLREDQFIHSVIRGCL 
SNMLFOCSLPDTTMLGDEPRKYLLRLYGAILOMRSCHKEGSEOAQKENEFQGAEAMVLE 
I l i l l i l l l l l ' ' l | , l  ¢ I I i i 111111111111 ~ • t l l l l l l l  
SHMLFOCSLPDSIASVGDEPRKVLLRLYGAILKM . . . . . . . . . . . . . . . . . .  GAEAMVLE 
volved in the catalytic, function of choline kinase from 
yeast, rat liver and human giioblastoma. 
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11}0 5'I'HFA 1LERSLGPKLYG I FPOGRLEQF l PSRRLr"TEELSLPD I SAE 1AEKHATFHG~H 
I I I i l  l I i 1111111111 i l l l l i l t l l l  i~  I I I i 1111  ~ t l l l i l l i l l l l l l l i l i l l  
159 5~MFAI LAERSLGPgLTGIFPOGRL£QFI PSRRLDTEELCLPDI 5AEIAEKMATFItGI4~ 
2.10 PFNKEPKWLFGIHEKYLKEVLRIKFTEESRIKKLHKLLSY~ILPLELENLRSLLESTPSPV 
I I  I I i i 111111111 I I  ~ :  i l i  ~ I I  ~ i .2_ • : :¢  I I I  ii I I I  I I i i i 11111111 : • ~ I i l  
219 PFNKr PK~dLFOTI'EKY LHQVLI~LKF 5REAR~/QQLHKFLS~'It LPL ELENLRSLLQYT RSPV 
300 VFCHNDCOEGNI LLLEGRENSEK~LMLI DFEYSSYhYRGFDIGNHFCENHYDYSYEKYP 
I l i l i l l t i l i l l l l l t  : i111111 I i l l  i 111111111 t I I I  t i l i i t i l i t i  ; l t l i l  
279 VFCHHDCEGN ILLLEGflENsEKnK LML l DFEYSS't'ItYRG FD [ GNHFCEWMYDTTY~YP 
380 F'FR,~,NI RKYPTKKQOLHF I SS'tLPAFQNDFENLSTEEKS I IKEEMLLEVNRFALASLtFLIt 
I l i l l t  i I l i l  i i 1111t i1111 | . . i t l i i i l l l { l l{ I ,  , i l l  a_ I i i I I I i I I I I i l l i l  
339 FFRAN I QKYPTffKQOLHF ISS?LTTFOttDEESLSSEEOSATKEDHLLEVNRFALASHFLII 
4ZO GLHS i¥O/".K 1551EFGYHD'/AGARFDA't FII~RKLGV 
t l l l l l l i l l l l l a i l l l  ~ I l l l l l l l l l  ~ l l l l l l l  
309 P.L HSI VOAK I SS I EFO'tHEY~,OhRFDhYFDQKRK LP.V 
Fig, 4. Sequence alignment of human glioblastoma choline kinase and 
rat l'ver choline kinase. The sequences were compared using the GEN- 
ETYX program (SDC Corp. Inc.) and aligned so that maximum 
matching was obtained. (Upper  line) Human 8]ioblastoma choline 
kinase; (lower line) rat liver choline kinase, The asterisks indicate 
identical amino acids, and the colons conservatively substituted amino 
acids, The figures at the left denote the positions of the left-end amino 
acids, 
At the nucleotide l vel, the open reading frames resem- 
bled each other, 68% identity. Compared with yeast 
choline kinase [3], significant sequence identity (28.7%) 
was observed in the carboxy-terminal regions (human, 
amino acids 292--427; yeast, 357-487), but not much in 
the anaino-terminal regions. The carboxy-terminal re- 
gion contained Brenner's phosphotransferase consen- 
sus (HXDhXXXNhhh ..... D, where h stands for large 
hydrophobic amino acids, FLIMVWY) [25] at positions 
303-329 (Fig. 3). We. previously showed that a trun- 
cated yeast choline kinase constructed by removing the 
amino-terminal 151 amino acids still exhibited slight but 
significant choline kinase activity [3]. Thus it is tempting 
to speculate that the carboxy-terminal region is in- 
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